期刊文献+

HER-2寡脱氧核苷酸-叶酸药物的生物学特性 被引量:1

The biospeciality of HER-2 oligodeoxynucleotides combined with FA
暂未订购
导出
摘要 目的研究HER-2寡脱氧核苷酸(oligodeoxynucleotides,ODN)与叶酸连接药物的生物学特性。方法 HER-2反义、正义和无义寡脱氧核苷酸与叶酸联接,形成ODN-FA,标记放射性核素锝(99mTc),与新鲜人血浆孵育1.5h、4h和6h,测定血浆蛋白结合率。在新鲜人血清37℃孵育 0.5h、2h、4h和6h,用纸层析法测定血清稳定性。结果 99mTc-ODN-FA的血浆蛋白结合率为反义、正义和无意义寡核苷酸分别为10.58%、12.24%和11.01%;6h血浆蛋白结合率明显升高,分别为 24.45%、23.58%和24.33%,差异具有显著意义(P<0.01)。99mTc-ASODN-FA、99mTc-SODN-FA和 99mTc-NODN-FA 6h放化纯分别为92.20%、92.12%和91.31%,与0.5 h相比略有降低,差异无显著意义。结论 HER-2寡脱氧核苷酸叶酸药物的血浆蛋白结合率6h时为24%,在血清中6h内稳定,能够满足体内外分析的要求。 Objective To study the biology speciality of protooncogene HER-2 oligodeoxynucleotides (ODN) combined with folic acid (FA). Methods HER-2 antisense oligodeoxynucleotide (ASODN), sense oligodeoxynucleotide (SODN) and nonsense oligodeoxynucleotide (NODN) were connected with folic acidCFA), then labeled by ^99mTc forming ^99mTc-ODN-FA which were incubated with fresh human plasma at 37℃ for 1.5, 4 and 6h, determined plasma protein binding percentage. ^99mTc-ODN-FA were incubated with fresh human serum at 37℃ for 0. 5, 2, 4 and 6h, then measured the stability in serum by paper chromatography(PC). Results The plasma protein binding percentages of ^99mTc-ODN-FA were ASODN 10. 58%, SODN 12. 24%, NODN 11.01% at 1.5h, respectively. The plasma protein binding percentages were evidently increased at 6h compared with 0. 5h which were ASODN 24. 45%, SODN 23. 58%, NODN 24. 33% at 1.5h, respectively (P〈0. 01). The radiochemical purity (RCP) of ^99mTc-ASODN-FA, ^99mTc-SODN-FA and ^99mTc-NODN-FA were 92. 20%, 92. 12% and 91.31% at 6h, respectively. RCP at 6h were lower than that at 0. 5h, but had no significant difference (P〉0. 05). Conclusion The biospeciality of HER-2 oligodeoxynucleotides combined with folic acid could satisfy the analysis request in vivo and vitro.
出处 《贵州医药》 CAS 2006年第5期394-396,共3页 Guizhou Medical Journal
基金 贵州省优秀科技教育人才省长专项资金资助项目(编号:黔省专合字(2005)36号)
关键词 HER-2 寡脱氧核苷酸 叶酸 血清稳定性 血浆蛋白结合率 HER-2 Oligodeoxynucleotides Folic acid Serum stabilityPlasma protein binding percentage
  • 相关文献

参考文献7

  • 1Leamon C.P,Reddy J.A.Folate-targeted chemotherapy[J].Advanced Drag Delivery Reviews,2004,56 (2004):1 127-1 141.
  • 2谢娟,郭坤亮,李少林.叶酸受体介导^(99m)Tc标记c-erbB2癌基因反义寡核苷酸的乳腺癌细胞摄取率[J].贵州医药,2005,29(1):13-15. 被引量:7
  • 3谢娟,刘方欣,王颖,李少林.^(99)Tc^m-EC-ASODN反义探针的合成和标记[J].核技术,2005,28(6):449-453. 被引量:7
  • 4Rait AS,Pirollo KF,Xiang L,et al.Tumor-targeting,systemically delivered antisense HER-2 chemosensitizeshuman breast cancer xenografts irrespective of HER-2 levels[J].Molecular medicine,2002,8(8):475-486.
  • 5Wang LX,Prakash RK,Stein CA,et al.Progress in the delivery of therapeutic oligonucleotides:Organ/cellular distribution and targeted delivery of oligonucleotides in vivo[J].Antisense & nucleic acid drug development,2003,13(3):169-189.
  • 6James P,Joanne Stekier,Samuel Demirdji,et al.Inhibition of the erbB-2 tyrosine kinase receptor in breast caner cells by phosphoromonothioate and phosphorodithioate antisense oligonucleotides[J].Nucleic Acids Research,1996,24(22):4 588-4 564.
  • 7R.Colomer,R.Lupus,S.S.Bacus,et al.erbB-2 ahtisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification[J].Br J Cancer,1994,70(5):819-825.

二级参考文献26

  • 1P Winnard Jr, F Chang, M Rusckowski, et ak Preparation and use of NHS-MAG- for Technetium-^99m labeling of DNA[J]. Nuclear Medicine & Biology, 1997, 24 : 425-432.
  • 2Reddy,-J-A, Low,-P-S. Folate-mediated targeting of therapeutic and imaging agents to cancers. Crit-Rev-Ther-Drug-Carrier-Syst, 1998- 15(6): 587-627.
  • 3Ginobbi P,Geiser TA,Ombres D, et al. Folic acid-polylysine carrier improves efficacy of c-myc antisense oligonucleotides on human melanoma (M14) cells. Anticancer Res,1997,17:29-35.
  • 4Orr RB, Kreisler A_R, Kamen BA. Similarity of folate receptor expression in - 38 cells to squamous cell carcinoma differentiation markers. J Natl Cancer Inst,1995,87: 299-303.
  • 5Konecny G, Untch M, Arboleda J, et al. Her-2/neu and Urokinase-type plasminogen activatior and its inhibitor in breast cancer[J]. Clin Cancer Res, 2001,7 (8) : 2448-2457.
  • 6Zhang-Y-M, Rusckowski-M, Liu-N, et al. Cationic liposomes enhance cellular/nuclear localization of 9^9m Tc-antisense oligonucleotides in target tumor cells[J]. Cancer-Biother- Radiopharm,2001,16(5) : 411-419.
  • 7Fereshteh Zareneyrizi, David J Yang, Chang-Sok Oh, et al. Synthesis of [^99m Tc] ethylenedicysteine- colchicine for evaluation of antiangiogenic effect[J]. Anti-Cancer Drugs, 1999,10: 685-692.
  • 8Seyfettin Ilgan, David J Yang, Tetsuya Higuchi, et al. ^99m Tc-Ethylenedicysteine-Folate: A New Tumor Imaging Agent Synthesis,Labeling and Evaluation in Animals[J].1998,13(6):427-435.
  • 9James P Vaughn,Joanne Stekler, Samuel Demirdji, et al.Inhibition of the erbB-2 tyrosine kinase receptor in breast cancer cells by phosphoromonothioate and phosphorodithioate antisense oligonucleotides [J]. Nucleic Acids Research, 1996,24 (22) : 4558-4564.
  • 10P Winnard Jr, F Chang, M Rusckowski, et ak Preparation and use of NHS-MAG3 for Technetium-99^m labeling of DNA[J]. Nuclear Medicine & Biology, 1997, 24 : 425-432.

共引文献10

同被引文献13

  • 1谢娟,郭坤亮,李少林.叶酸受体介导^(99m)Tc标记c-erbB2癌基因反义寡核苷酸的乳腺癌细胞摄取率[J].贵州医药,2005,29(1):13-15. 被引量:7
  • 2Bundred NJ.Prognostic and predictive factors in breast cancer[J].Cancer Treat Rev,2001,27 (3):137-142.
  • 3Hideko Yamauchi,Vered Stearns,Daniel F Hayes.When is a tumor Marker ready for prime time? A case study of c-erbB 2 as a predictive factor in breast cancer[J].Journal of Clinical Oncology,2001,19(8):2 334-2 356.
  • 4Michele A.Bonham,Stephen Brown,Ann L.Boyd,et al.An assessement of the antisense properties of RNase Hcompetent and steric-blocking oligomers[J].Nucleic Acids Research,1995,23(7):1 197-1 203.
  • 5Koukourakis MI,Giatromanolaki A,Galazios G,et al.Molecular analysis of local relapse in high-risk breast cancer patients:canradiotherapy fractionation and time factors make a difference[J]? Br J Cancer,2003,10,88(5):711-717.
  • 6Koukourakis MI.Hypofractionated and accelerated radiotherapy with amifostine cytoprotection (HypoARC):a new concept in radiotherapy and encouraging results in breast cancer[J].Semin Oncol,2002,29(6 Suppl 19):42-46.
  • 7Pietras RJ,Poen JC,Gallardo D,et al.Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cellsoverexpressing this oncogene[J].Cancer Res.1999,59:1 347-1 355.
  • 8Harari D,Yaraden Y.Molecular mechanisms underlying erbB-2/HER-2 action in breast cancer[J].Oncogene,2000,19(53):6 102-6 114.
  • 9Tsutsui,Shinichi Ohno,Shinji Murakami,et al.Prognostic value of c-erbB2 expression in breast cancer[J].Journal of Surgical Oncology,2002,79(4):216-223.
  • 10Cho HS,Mason K,Ramyar KX,et al.Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab[J].Nature,2003,421 (6 924):756-760.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部